CAR T cell Therapy Is an Advanced Form of Treatment That Is Practiced Worldwide to Help Patients Suffering from Chronic Diseases Such As Cancer

 

CAR T cell therapy is the most commonly used form of complementary immunosuppression today in regions such as UK, US, and Italy, and many people are aware of it through the publicity and marketing efforts of global pharmaceutical companies. Chimeric antigen receptor T cells (CAR T cell) are genetically engineered in a lab to generate a synthetic T cell receptor for application in immunotherapy. Many patients are now using this treatment for their chronic illnesses such as chronic hepatitis, cancer, infectious mononucleosis, Crohn's disease, etc.

When cancerous cells invade the body, they secrete a protein called interferon-gamma, which can damage healthy cells. This causes the healthy cells to secrete antibodies called macrophages, which chase the interferon-gamma away. This is how the immune system reacts to cancer and results in remission of the illness. The CAR T cells are introduced into the patient's body at this time, and once they start to recognize the cancerous cells they fire off the Macrophage antibodies and cause a rapid onset of remission.

Unlike other forms of immunotherapies, such as chemotherapy, mesothelioma, etc., there is no need for long-term administration of medication and therefore no loss of overall health. There are many different types of immunotherapy available for cancer treatment, but the most widely used is CAR T cell therapy. Currently, cancer cases are increasing all over the world, owing to the pollution, lifestyle choices, and unhealthy habits of people. For instance, according to the American Cancer Society, the number of new cancer cases in the U.S, in 2020 was approximately 1.8 million, while cancer-related deaths were approximately 606,520. In such scenarios pharmaceutical companies across the globe have been creating new medicines and treatments to aid the CAR T Cell therapy, such as Janssen and Legend Biotech has developed a new ciltacabtagene autoleucel, known as cilta-cel, which can be used to treat adults with refractory or relapsed multiple myeloma. Janssen and Legend Biotech is still waiting for the U.S. Food and Drug Administration (FDA) to approve the drug.

Some precautions must be taken to achieve success in the treatment. Most people who have undergone CAR T cell therapy have also undergone several weeks of chemotherapy, however, this is not necessary with this form of treatment. There is very minimal risk associated with the CAR T cell therapy.